A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label dose-escalation study to determine the maximum tolerated dose
(MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is
anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of
the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.